Key Highlights
Tezspire (tezepelumab) with no phenotypic (eosinophilic or allergic) or biomarker restriction will be the new game-changer in the severe asthma marketDepemokimab is an excellent market replacement for GSKs’ Nucala as of its improved binding affinity and longer duration of action as a single doseNon-eosinophilic asthma (NEA), which is an orphan asthma endotype, has a scarcity of effective specialized therapies
Asthma is the most prevalent chronic illness in children and is a serious non-communicable disease (NCD) that affects both children and adults. People with asthma may require emergency medical attention if their asthma symptoms are severe, an...
